CES Unveiled in Amsterdam Highlights Tech Improving Lives
17.10.2019 19:09:00 EEST | Business Wire | Press release
The Consumer Technology Association (CTA) ® today made several announcements at CES Unveiled in Amsterdam, an official CES® 2020 preview event. Executives, influential media and prominent industry influencers gathered at the record-breaking event to celebrate the latest European innovations and experience what to expect at CES 2020.
CTA announced that eight companies from the Netherlands and the surrounding region were announced as CES 2020 Innovation Honorees. Best of Innovation honorees include Dutch company Hydraloop Systems BV in the Sustainability, Eco-Design & Smart Energy category and British company Valerann in the Smart Cities category.
“Europe is a hotbed for innovation consistently driving our industry forward and we saw the promise and power of technology at CES Unveiled in Amsterdam,” said Karen Chupka, EVP, CES. “CES 2020 will showcase the most innovative tech from Europe that truly has the potential to make people’s lives better.”
The remaining honorees will be revealed at CES Unveiled in Paris on Oct. 22., 2019, and CES Unveiled New York on Nov. 7, 2019. Honorees will be posted online at CES.tech starting Nov. 7, 2019 and many will showcase their winning products at CES 2020, Jan. 7-10, in Las Vegas.
In its third year, CES Unveiled in Amsterdam set records by selling out exhibit space and bringing together more than 1,500 attendees from nearly 50 countries. The event also featured government and industry leaders from the Netherlands and surrounding regions including, Pete Hoekstra, U.S. Ambassador to the Netherlands; Mona Keijzer, Netherlands State Secretary for Economic Affairs and Climate Policy; Femke Halsema, Mayor of Amsterdam; and Corinne Vigreux, co-founder of TomTom and founder of CODAM.
Europe welcomed more than 16,000 attendees to CES 2019 and continues to lead innovation by example. The European Union had a strong presence at CES Unveiled in Amsterdam, featuring leaders including, Katerina Borunska, Policy Officer, European Commission; Hubert Cottogni, Director, Head of Mandate Management, European Investment Fund; and Els Sweeney-Bindels, Head of EIB Amsterdam Office, European Investment Bank. CES Unveiled promotes the continued value it shares with Europe through partnerships across government, business and research.
TechLeap.NL also announced their new visual identity and the 50 startups they are bringing to CES 2020 as part of Eureka Park. HRH Prince Constantijn van Oranje, Special Envoy at TechLeap.NL, also discussed why CES is important for Dutch startups and why he is working to make the Netherlands the best place for tomorrow’s leaders in technology.
Owned and produced by CTA, CES 2020, the world’s largest and most influential tech event, will run Jan. 7-10, 2020, in Las Vegas, NV and provide access to the most transformative tech across various marketplaces, such as 5G connectivity, artificial intelligence, augmented and virtual reality, smart home, smart cities, vehicles, digital health and more. Industry leaders and rising stars will come together again to pioneer future innovation driving the ever-evolving tech industry.
Registration for CES 2020 is now open. For the latest exhibitor news and show announcements, visit CES.tech.
About CES:
CES® is the largest, most influential tech event in the world – the proving ground for breakthrough technologies and global innovators. This is where the world's biggest brands do business and meet new partners, and the sharpest innovators hit the stage. Owned and produced by the Consumer Technology Association (CTA)®, CES features every aspect of the tech sector. Learn more at CES.tech and follow CES on social.
About Consumer Technology Association:
As North America’s largest technology trade association, CTA® is the tech sector. Our members are the world’s leading innovators – from startups to global brands – helping support more than 18 million American jobs. CTA owns and produces CES® – the largest, most influential tech event on the planet. Find us at CTA.tech. Follow us @CTAtech.
UPCOMING EVENTS
-
CES Unveiled in Paris
October 22 – Paris, France -
Consumer Technology Hall of Fame
November 6, 2019 – New York, NY -
CES Unveiled New York
November 7 – New York, NY -
CES Unveiled Las Vegas
January 5, 2020 – Las Vegas, NV -
CES 2020
January 7-10, 2020 – Las Vegas, NV
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191017005692/en/
Contact information
Justin Siraj
703-907-7415
jsiraj@CTA.tech
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom